A stable composition obtained by enzymatic oxidation of a halide thiocyanate mixture, including at least one ion selected from the group of the I2SCN— ions and the I(SCN).sub.2— ions, the composition being free of hypothiocyanite ions. In an embodiment, the composition further includes iodine thiocyanate ISCN. This disclosure also relates to a method for preparing the stable composition and to the uses thereof.

A composition comprising a) a curable resin or prepolymer component having ethylenically unsaturated polymerizable groups, b) an ethylenically unsaturated polymerizable monomer, c) an oxidoreductase and d) at least one of an organic peroxide and hydrogen peroxide, wherein the composition comprises between 0.0 and 20.0% by weight of water, calculated on the total weight of the composition.

Methods of making engineered protein-based materials, nanofibers, and biofilms from bacterial amyloid-based structures that are capable of mediating long-range electron transport are provided.

The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and lactoperoxidase and/or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.3 to 20.

The present invention provides a polypeptide having peroxidase activity and comprising an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 3, wherein said amino acid sequence comprises at least one amino acid exchange compared to SEQ ID NO: 1, wherein said at least one amino acid exchange is an exchange of the amino acid P146 or of the amino acid N275 of SEQ ID NO: 1. The invention further relates to a nucleic acid molecule comprising a sequence encoding said polypeptide, an expression vector comprising said nucleic acid molecule, and a host cell comprising said expression vector. Moreover, methods for producing said polypeptide and compositions and kits comprising said polypeptides are provided.

Components for enabling immunodection of MT-45 are described including immunogens, antibodies derived from the immunogens, immunoassay methods, detecting agents and kits.

A method and a mineral wool product include a multiple of lamellae, such as a sandwich panel core. The product includes a plurality of lamellae cut from a mineral wool web, and bonded together by applying an adhesive on the surfaces of two adjacent lamellae to form a web-like product, wherein the adhesive comprises at least one hydrocolloid.

The disclosure provides rabbit monoclonal antibodies against the spike S1 protein of SARS-CoV-2 and uses thereof. The antibody comprises: a V.sub.H CDR1 selected from the group consisting of SEQ ID NO: 1-7; a V.sub.H CDR2 selected from the group consisting SEQ ID NO: 8-14; a V.sub.H CDR3 selected from the group consisting of SEQ ID NO: 15-21; a V.sub.L CDR1 selected from the group consisting SEQ IDN NO: 22-28; a V.sub.L CDR2 selected from the group consisting of SEQ ID NO: 29-35; and a V.sub.L CDR3 selected from the group consisting of SEQ ID NO: 36-42. The antibodies can be used for a rapid test or screening of SARS-CoV-2 infection. The antibodies can also be used for treating SARS-CoV-2 infection.

The disclosure provides rabbit monoclonal antibodies against the nucleocapsid protein of SARS-CoV-2 and uses thereof. The antibody comprises: a V.sub.H CDR1 selected from the group consisting of SEQ ID NO: 1-7; a V.sub.H CDR2 selected from the group consisting SEQ ID NO: 8-14; a V.sub.H CDR3 selected from the group consisting of SEQ ID NO: 15-21; a V.sub.L CDR1 selected from the group consisting SEQ ID NO: 22-28; a V.sub.L CDR2 selected from the group consisting of SEQ ID NO: 29-35; and a V.sub.L CDR3 selected from the group consisting of SEQ ID NO: 36-42. The antibodies can be used for a rapid test or screening of SARS-CoV-2 infection and detecting SARS-CoV-2 nucleocapsid protein.

The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.